# The Institute for Cancer Research

Canonical: https://abierto.us/vendors/the-institute-for-cancer-research-ff1xvjmdyvr1

- UEI: FF1XVJMDYVR1
- CAGE: 1RAF4
- Location: Philadelphia, PA
- Awards in window: 2 (2 transactions), -$16,800 obligated, July 6, 2026 to July 7, 2026

## Awarding agencies

- National Institutes of Health: 2 awards, -$16,800

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $0
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): -$16,800

## Competition

- Full and Open Competition: 1 awards
- Competed Under SAP: 1 awards

## Largest awards

- 75N91022F00002 (delivery order): $0, NIH NCI. Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Task Order Title: Next Generation Gp130/Il-6/Stat3 Inhibitors for the Prevention of Colitis-Associated Colorectal Cancer. https://www.usaspending.gov/award/CONT_AWD_75N91022F00002_7529_75N91019D00022_7529/
- 75N92E21P00142 (purchase order): -$16,800, National Institutes of Health Nhgri. The Elnitski Lab Is Purchasing Normal, Liver, and Prostate Cancer Patient Plasma.[21-004028]. https://www.usaspending.gov/award/CONT_AWD_75N92E21P00142_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/the-institute-for-cancer-research-ff1xvjmdyvr1.